• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Renovaro Inc. filed SEC Form 8-K: Leadership Update

    6/5/25 4:02:04 PM ET
    $RENB
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $RENB alert in real time by email
    false 0001527728 0001527728 2025-05-30 2025-05-30 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

     

     

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION

    Washington, DC 20549

     

    FORM 8-K

     

    CURRENT REPORT

     

    Pursuant to Section 13 or 15(d) of the
    Securities Exchange Act of 1934

     

    Date of Report (Date of earliest event reported): May 30, 2025

     

    RENOVARO INC.

    (Exact name of registrant as specified in its charter)

     

    Delaware   001-38758   45-2259340
    (State or other jurisdiction   (Commission File Number)   (I.R.S. Employer
    of incorporation)       Identification No.)

     

    2080 Century Park East, Suite 906

    Los Angeles, CA 90067
     
    (Address of principal executive offices)

     

    +1 (305) 918-1980

    (Registrant’s telephone number, including area code)

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

     

    ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
    ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
    ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
    ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

     

    Securities registered pursuant to Section 12(b) of the Act:

     

    Title of Each Class   Trading Symbol   Name of Each Exchange on Which Registered
    Common Stock, par value $0.0001 per share   RENB   The Nasdaq Stock Market LLC

     

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

     

    Emerging growth company ☐

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     

     

     

    Item 5.02Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

     

    On May 30, 2025, Maurice van Tilburg notified Renovaro Inc. (the “Company”) of his intent to resign from the office of Chief Executive Officer of GEDi Cube B.V., a wholly-owned indirect subsidiary of the Company, which resignation was effective May 30, 2025. Mr. van Tilburg’s resignation is not as a result of any disagreement with the Company or its Board of Directors, on any matter relating to the Company’s operations, policies or practices. Mr. van Tilburg will continue to serve on the Company’s Board of Directors.

     

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

      RENOVARO INC.
       
      By: /s/ Nathen Fuentes
        Name: Nathen Fuentes
    Title: Chief Financial Officer

     

    Date: June 5, 2025

     

     

     

    Get the next $RENB alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $RENB

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $RENB
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Large owner William Anderson Wittekind disposed of 350,000 shares, decreasing direct ownership by 9% to 3,353,878 units (SEC Form 4)

      4 - RENOVARO INC. (0001527728) (Issuer)

      3/12/25 8:12:50 AM ET
      $RENB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Van Tilburg Maurice was granted 250,000 shares (SEC Form 4)

      4 - RENOVARO INC. (0001527728) (Issuer)

      2/25/25 1:33:34 PM ET
      $RENB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Chief Financial Officer Fuentes Nathen

      4 - RENOVARO INC. (0001527728) (Issuer)

      2/25/25 1:29:46 PM ET
      $RENB
      Biotechnology: Pharmaceutical Preparations
      Health Care